

10. A method according to Claim 9, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

11. A method according to Claim 8, wherein the composition is an oral formulation.

12. A method according to Claim 8, wherein the composition is a topical ophthalmic, or intraocular formulation.

13. A method according to Claim 10, wherein the composition is an oral formulation.

14. A method according to Claim 10, wherein the composition is a topical ophthalmic, or intraocular formulation.

A new page showing the claims as amended is included with this Amendment.

#### **REMARKS**

Claims 1 – 7 have been cancelled; Claim 9 has been amended; Claims 8 – 14 are pending.

Claims 1, 2, 4, 5, 8, 9, 11, and 12 have been rejected under 35 U.S.C. § 102(b) as being anticipated by Takeda Chem Ind., Ltd. (a copy of the full reference and a machine translation are included with this Amendment). In view of the amendments, this rejection is moot.

Claims 3 and 6 have been rejected under 35 U.S.C. § 102(b) as being anticipated by Graul, et al. In view of the amendments, this rejection is now moot.

Claims 7, 10, 12, and 14 have been rejected under 35 U.S.C. § 103 as being unpatentable over Rathone, et al. Applicants respectfully traverse the rejection.

Rathone, et al. disclose that AIT-082 enhances NGF synthesis. It does not suggest

ophthalmic use. Reconsideration is respectfully requested.

Respectfully submitted,

Date May 9, 2002

By: Sally Yeager  
Sally Yeager  
Registration No. 32,757

Address for Correspondence:



**26356**  
Attorney Docket No: 1719F US  
PATENT TRADEMARK OFFICE